Eiger BioPharmaceuticals Inc

NASDAQ:EIGR   3:59:50 PM EDT
6.77
-0.01 (-0.15%)
Products, Regulatory

Eiger's Single-Dose Peginterferon Lambda For Covid-19 Reduced Risk Of Hospitalization Or Er Visits By 50% In A Predominantly Vaccinated Population In Phase 3 Together Study

Published: 03/17/2022 13:58 GMT
Eiger BioPharmaceuticals Inc (EIGR) - Eiger's Single-dose Peginterferon Lambda for Covid-19 Reduced Risk of Hospitalization Or Er Visits by 50% in a Predominantly Vaccinated Population in Phase 3 Together Study.
Eiger Biopharmaceuticals Inc - Primary Endpoint Achieved Across Multiple Sars-cov-2 Variants, Including Omicron.
Eiger Biopharmaceuticals Inc - Plans to Submit Data to FDA for Emergency Use Authorization for Phase 3 Together Study.